Pacira BioSciences (NASDAQ: PCRX) isn't a shooting star, but the company has been steadily increasing revenue and was profitable in 2020 for only the second time since its initial public offering (IPO) in 2011. The company specializes in developing presurgical and postsurgical non-opioid pain and regenerative health solutions.
The company's stock is up more than 128% in the past year, and might be getting ready to go higher. It received good news earlier this week when the U.S. Food and Drug Administration approved the expanded label of its non-opiod painkiller, Exparel, for use with pediatric patients ages six and over, in a single dose, for postsurgical pain relief. How big of a deal is this for investors?
Image source: Getty Images.
For further details see:
After a Label Expansion, Is This Under-the-Radar Biotech a Buy?